Use of the CD19 count in a primary care laboratory as a screening method for B-cell chronic lymphoproliferative disorders in asymptomatic patients with lymphocytosis : Clinical Chemistry and Laboratory Medicine uses cookies, tags, and tracking settings to store information that help give you the very best browsing experience.
To understand more about cookies, tags, and tracking, see our Privacy Statement
I accept all cookies for the De Gruyter Online site

Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R. / Tsongalis, Gregory J.

IMPACT FACTOR 2014: 2.707
Rank 6 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2014: 0.741
Source Normalized Impact per Paper (SNIP) 2014: 1.011
Impact per Publication (IPP) 2014: 2.310



30,00 € / $42.00 / £23.00

Get Access to Full Text

Use of the CD19 count in a primary care laboratory as a screening method for B-cell chronic lymphoproliferative disorders in asymptomatic patients with lymphocytosis

1–3, , / Kathelijn Fischer4 / Wim Verweij1 / Arend J. van Houte5 / Arnon P. Kater3 / Douwe H. Biesma2, 6

1Primary Care Laboratory, SALTRO, Utrecht, The Netherlands

2Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands

3Department of Haematology, Academic Medical Centre Amsterdam, The Netherlands

4Department of Epidemiology, Julius Centre, Utrecht, The Netherlands

5Departments of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands

6Department of Internal Medicine, University Medical Centre, Utrecht, The Netherlands

Corresponding author: G. Doreen te Raa, MD, Department of Haematology, Academic Medical Centre Amsterdam, P.O. Box 22600, 1100 DD Amsterdam, The Netherlands Phone: +31 6 18296018

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 49, Issue 1, Pages 115–120, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2011.018, November 2010

Publication History

Published Online:


Background: Detection of absolute and relative lymphocytosis in otherwise asymptomatic elderly patients is very common in the primary care setting and frequently results in referral for screening of lymphoproliferative disorders. Since many B-cell chronic lymphoproliferative disorders (B-CLPD) are indeed asymptomatic at diagnosis in most patients with lymphocytosis, no sign of such a disorder is usually detected. Currently, specific guidelines for screening of patients with lymphocytosis are lacking. We investigated the practicability and clinical value of a single colour CD19 count performed by a primary care laboratory in order to improve the diagnostic follow-up of patients with lymphocytosis in a primary care laboratory.

Methods: The capability of detecting monoclonal B-cell lymphocytosis and B-CLPD by CD19, was first confirmed in patient samples with known B-CLPD. Next, in a previously defined geographic area, a CD19 count was performed on all samples for patients aged ≥40 years with relative or absolute lymphocytosis but without neutropenia. Clinical follow-up, with a median of 4 years, was performed using both a survey among the requesting general practitioners and by analysis of the records of the referral hospitals within the borders of the defined area.

Results: A total of 520 cases with asymptomatic lymphocytosis were identified. In all cases, the CD19 count was performed; 207 (40%) showed increased values and 313 (60%) showed normal values. An increase in CD19 proved highly sensitive for detection of B-CLPD (98%, 95% CI; 94%–100%) with a high positive predictive value (57%, 95% CI; 50%–63%). The area under curve, the receiver-operating characteristic curve of the CD19 count (0.93, 95% CI; 0.91–0.96), was significantly higher compared to the absolute lymphocyte count (0.86, 95% CI; 0.83–0.89), especially in patients with moderate lymphocytosis.

Conclusions: This study indicates that the CD19 count, performed by a primary care laboratory, is feasible and a promising tool for initial screening of lymphocytosis to discriminate B-CLPD from benign causes of lymphocytosis.

Keywords: absolute lymphocyte count; B-cell chronic lymphoproliferative disorder; CD19; chronic lymphocytic leukaemia; diagnosis; monoclonal B-cell lymphocytosis

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

G. Doreen te Raa, Sanne H. Tonino, Ester B. M. Remmerswaal, Arend Jan van Houte, Harry R. Koene, Marinus H. van Oers, and Arnon P. Kater
Leukemia & Lymphoma, 2012, Volume 53, Number 11, Page 2321
Arnaud Jean, Catherine Boutet, Bernard Lenormand, Marie-Paule Callat, Gérard Buchonnet, Carole Leclerc, and Marc Vasse
Clinical Chemistry and Laboratory Medicine, 2011, Volume 49, Number 11

Comments (0)

Please log in or register to comment.